HOUSTON / LOS ANGELES — When Ozempic and Wegovy exploded onto the American health scene, they changed the conversation around obesity and diabetes forever. Millions of Americans — many in major cities where obesity rates climb well above the national average — rushed to get prescriptions. But for a significant number of patients, the side effects proved too difficult to bear: persistent nausea, vomiting, gastrointestinal distress, and a troubling loss of muscle mass.
Now, researchers at Karolinska Institutet and Stockholm University have published a study in the journal Cell describing a new oral compound that targets the same metabolic problems — but works in a completely different way.
